Aratana Therapeutics is a pioneer in pet therapeutics focused on licensing, developing and commercializing innovative therapeutics for dogs and cats. Its goal is to provide veterinarians and pet owners with new therapeutics that are driven by science and specifically made for pets. The Сompany's pipeline includes therapeutic candidates for the potential treatment of pain, inappetence, viral diseases, allergy, cancer and other serious medical conditions. Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets.


Employee Rating

0More
TypePublic
HQLeawood, US
Founded2010
Size (employees)84 (est)-1%
Websitearatana.com
Aratana Therapeutics was founded in 2010 and is headquartered in Leawood, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Aratana Therapeutics

Louise MawHinney

Louise MawHinney

CFO
Ernst Heinen

Ernst Heinen

Head of Drug Evaluation and Development
John Ayers

John Ayers

General Counsel & Secretary
James Miller

James Miller

Controller
Marie-Paul Lachaud

Marie-Paul Lachaud

Head of Business & Product Development Europe
Show more

Aratana Therapeutics Office Locations

Aratana Therapeutics has offices in Leawood, San Diego and Leuven
Leawood, (HQ)
11400 Tomahawk Creek Pkwy, Suite 340
San Diego,
10451 Roselle St, Suite 200A
Leuven,
1 Ambachtenlaan
Show all (3)
Report incorrect company information

Aratana Therapeutics Financials and Metrics

Aratana Therapeutics Revenue

Aratana Therapeutics's revenue was reported to be $25.57 m in FY, 2017
USD

Revenue (Q3, 2018)

21.6m

Gross profit (Q3, 2018)

19.4m

Gross profit margin (Q3, 2018), %

89.9%

Net income (Q3, 2018)

8.8m

EBIT (Q3, 2018)

9.4m

Market capitalization (4-Dec-2018)

309.7m

Closing stock price (4-Dec-2018)

6.4

Cash (30-Sep-2018)

54.3m
Aratana Therapeutics's current market capitalization is $309.7 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

123.0k767.0k678.0k38.6m25.6m

Revenue growth, %

524%(12%)5586%

Cost of goods sold

108.0k365.0k3.1m16.4m

Gross profit

15.0k313.0k35.4m9.2m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

176.0k300.0k43.0k156.0k230.0k229.0k172.0k38.0m40.0k3.8m5.2m6.2m4.0m4.9m21.6m

Cost of goods sold

110.0k109.0k138.0k19.0k1.7m286.0k3.1m3.7m3.7m536.0k1.3m2.2m

Gross profit

46.0k121.0k91.0k153.0k36.3m(246.0k)701.0k1.5m2.5m3.5m3.6m19.4m

Gross profit Margin, %

29%53%40%89%95%(615%)18%28%40%87%73%90%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

41.1m9.8m26.8m87.3m66.9m

Accounts Receivable

352.0k60.0k87.0k2.4m

Inventories

55.0k427.0k1.3m11.1m13.6m

Current Assets

48.5m99.9m89.0m101.5m85.2m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(4.3m)(38.8m)(84.1m)(33.6m)(47.5m)

Depreciation and Amortization

395.0k2.0m1.8m991.0k1.2m

Inventories

(372.0k)(879.0k)(15.0m)(3.2m)

Accounts Payable

1.5m(1.1m)(117.0k)6.2m62.0k
USDY, 2018

Financial Leverage

1.3 x
Show all financial metrics
Report incorrect company information

Aratana Therapeutics Online and Social Media Presence

Embed Graph
Report incorrect company information

Aratana Therapeutics News and Updates

Aratana Therapeutics to Report Third Quarter 2018 Financial Results

LEAWOOD, Kan., Oct. 22, 2018 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics for dogs and cats, will host a live conference call on Friday, November 2, 2018 at 8:30 ...
Report incorrect company information

Aratana Therapeutics Blogs

Aratana Therapeutics Reports Third Quarter 2018 Financial Results

For the third quarter ended September 30, 2018, Aratana reported total net revenues of $21.6 million and net income of $8.8 million or $0.19 diluted earnings per share. The net revenues for the quarter included a $15.0 million commercial milestone, which resulted in profitability for the quarter. T…

Aratana Therapeutics to Present at CL King and Associates Best Ideas Conference

The Company plans on presenting at CL King & Associates Best Ideas Conference on Thursday, September 13, 2018 at 1:15 p.m. ET in New York City. The post Aratana Therapeutics to Present at CL King and Associates Best Ideas Conference appeared first on Aratana Therapeutics.

NOCITA® (bupivacaine liposome injectable suspension)

The U.S. Food and Drug Administration’s Center for Veterinary Medicine (CVM) approved the supplemental New Animal Drug Application (NADA) to expand the NOCITA label. The post NOCITA® (bupivacaine liposome injectable suspension) appeared first on Aratana Therapeutics.

Aratana Therapeutics Reports Second Quarter 2018 Financial Results

The Company announced its second quarter 2018 financial results and will host a live conference call on Friday, August 3, 2018 at 8:30 a.m. ET to discuss financial results from the quarter ended June 30, 2018. The post Aratana Therapeutics Reports Second Quarter 2018 Financial Results appeared firs…

Aratana Therapeutics to Report Second Quarter 2018 Financial Results

The Company will host a live conference call on Friday, August 3, 2018 at 8:30 a.m. ET to discuss financial results from the second quarter ended June 30, 2018. The post Aratana Therapeutics to Report Second Quarter 2018 Financial Results appeared first on Aratana Therapeutics.

Aratana Therapeutics Files for FDA Approval of NOCITA® (bupivacaine liposome injectable suspension) Label Expansion

The Company announced it submitted a supplemental New Animal Drug Application (NADA) for NOCITA® (bupivacaine liposome injectable suspension) with the U.S. Food and Drug Administration’s Center for Veterinary Medicine (CVM). The post Aratana Therapeutics Files for FDA Approval of NOCITA® (bupivacai…

Aratana Therapeutics Company Life and Culture

Report incorrect company information

Aratana Therapeutics Frequently Asked Questions

  • When was Aratana Therapeutics founded?

    Aratana Therapeutics was founded in 2010.

  • Who are Aratana Therapeutics key executives?

    Aratana Therapeutics's key executives are Louise MawHinney, Ernst Heinen and John Ayers.

  • How many employees does Aratana Therapeutics have?

    Aratana Therapeutics has 84 employees.

  • What is Aratana Therapeutics revenue?

    Latest Aratana Therapeutics annual revenue is $25.6 m.

  • What is Aratana Therapeutics revenue per employee?

    Latest Aratana Therapeutics revenue per employee is $304.4 k.

  • Who are Aratana Therapeutics competitors?

    Competitors of Aratana Therapeutics include Cyclacel Pharmaceuticals, Rodeo Therapeutics and BlackThorn Therapeutics.

  • Where is Aratana Therapeutics headquarters?

    Aratana Therapeutics headquarters is located at 11400 Tomahawk Creek Pkwy, Suite 340, Leawood.

  • Where are Aratana Therapeutics offices?

    Aratana Therapeutics has offices in Leawood, San Diego and Leuven.

  • How many offices does Aratana Therapeutics have?

    Aratana Therapeutics has 3 offices.